A Volatile Share Price Masks Some Of The Progress At Inogen
Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage.
What's Going On With MedTech Focused Inogen Stock On Wednesday?
Medical Technology company Inogen Inc INGN reported a fourth-quarter adjusted EPS loss of 24 cents, compared to a loss of 83 cents a year ago, beating the consensus loss of 61 cents.
INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up
Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.
Inogen, Inc. (INGN) Q4 2024 Earnings Call Transcript
Inogen, Inc. (NASDAQ:INGN ) Q4 2024 Earnings Conference Call February 25, 2025 5:00 PM ET Company Participants Ryan Peterson – Investor Relations Kevin Smith – President and Chief Executive Officer Mike Bourque – Chief Financial Officer Conference Call Participants Operator Welcome to Inogen's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates
Inogen (INGN) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $1.14 per share a year ago.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach
INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.
Inogen (INGN) Moves to Strong Buy: Rationale Behind the Upgrade
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Inogen Stock Gains Following Solid Preliminary Q4 Revenues
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen (INGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
